A Phase I With Dose Expansion to Determine the Maximum Tolerated Dose of Liposomal Doxorubicin in Combination With Seliciclib for the Treatment of Patients With Metastatic Triple Negative Breast Cancer.

Trial Profile

A Phase I With Dose Expansion to Determine the Maximum Tolerated Dose of Liposomal Doxorubicin in Combination With Seliciclib for the Treatment of Patients With Metastatic Triple Negative Breast Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Seliciclib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jun 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 26 Mar 2012 Planned end date changed from 1 Jul 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
    • 26 Mar 2012 Planned initiation date changed from 1 Jul 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top